|
|
Article: A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis.(Original Research)
- Article from:
- Alternative Medicine Review
- Article date:
- June 1, 2008
- Author:
CopyrightCOPYRIGHT 2008 Thorne Research Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abstract
In a placebo-controlled clinical trial, the dietary supplement XP-828L (commercialized as Dermylex[TM]) demonstrated potential to reduce symptoms associated with mild-to-moderate psoriasis at a dose regimen of 5 g daily for 56 days. However, recent in vivo data in humans and animals suggest a daily dose of 800 mg could be more efficient than a 5-g dose. However, no well-structured clinical study has confirmed this hypothesis. The goal of the present study is to examine the effect of XP-828L at a daily dose of 800 mg on the quality of life and disease severity in patients with mild-to-moderate psoriasis. XP-828L at 800 mg per day (n=16) or placebo (n=10) ...
Related newspaper, magazine, and journal articles:
|
|
Article: PhotoMedex Announces CareFirst BlueCross BlueShield will ...
Business Wire;
December 11, 2001 ;
700+ words
... ... Committee of CareFirst BlueCross BlueShield informed the Company that the medically necessary treatment of mild to moderate psoriasis utilizing the PhotoMedex XTRAC(TM) laser system has met their criteria for coverage. A written Medical Policy ...
|
|